Kurokawa, Yukinori
Doki, Yuichiro
Kitabayashi, Ryo
Yoshikawa, Takaki
Nomura, Takashi
Tsuji, Kunihiro
Goto, Masahiro
Cho, Haruhiko
Hihara, Jun
Hiki, Naoki
Nunobe, Souya
Mizusawa, Junki
Boku, Narikazu
Terashima, Masanori
Funding for this research was provided by:
National Cancer Center Research and Development Fund (29-A-3, 2020-J-3, 2023-J-03)
Osaka University
Article History
Received: 8 October 2023
Accepted: 19 November 2023
First Online: 5 January 2024
Declarations
:
: Yukinori Kurokawa and Yuichiro Doki have received research funding and lecture fees from Taiho Pharmaceutical, Ono Pharmaceutical, Yakult Honsha, Eli Lilly Japan, and Daiichi Sankyo outside of the submitted work. Haruhiko Cho has received lecture fees from Yakult Honsha outside of the submitted work. Junki Mizusawa has received lecture fees from Taiho Pharmaceutical outside the submitted work; His spouse an employee of Pfizer. Narikazu Boku has received research funding from Ono Pharmaceutical and Takeda Pharmaceutical and lecture fees from Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squib Japan, Eli Lilly Japan, and Daiichi Sankyo outside of the submitted work. Masanori Terashima has received personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squib Japan, Yakult Honsha, Takeda Pharmaceutical, Eli Lilly Japan, Pfizer Japan, Daiichi Sankyo, Johnson and Johnson, Medtronic Japan, Intuitive Japan, and Olympus outside of the submitted work.
: All procedures performed in studies involving human participants were in accordance with the Japanese Clinical Trials Act and the related regulations and with the 1964 Helsinki Declaration and its later amendments. Informed consent to be included in the study was obtained from all patients.